Elevated T-β-MCA antagonizes theintestinal FXR/FGF19 signaling pathway, thereby stimulating bile acidsynthesis and improving obesity and diabetes outcomes.10 Collectively, these findings suggest that dietaryand pharmacological interventions can reshape the gut microbiota andbile acid profiles, potentially influencing gut health and liver diseaseprogression through the FXR/FGF19 signaling pathway. This evidence concerns the gene NR1H4 and obesity disorder.